### 510(k) SUMMARY

JUN 0 4 2014

### A. Name, Address, Phone and Fax Number of Applicant

Teleflex Medical, Incorporated 2917 Weck Drive Research Triangle Park, NC 27709 USA

Phone: 919-433-8050 Fax: 919-433-4996

#### **B.** Contact Person

Angela Bouse Senior Regulatory Affairs Specialist

### C. Date Prepared

June 3, 2014

#### D. Device Name

Trade Name:

SOFTECH® Plus ETCO2 Cannula

Classification Name:

Analyzer, Gas, Carbon-Dioxide, Gaseous-Phase

Product Code:

**CCK** 

Additional Product Code:

CAT

Regulation Number:

868.1400

Classification:

H

Classification Panel:

Anesthesiology

### E. Predicate Device

This submission demonstrates substantial equivalence to the predicate device Double Lumen Oxygen Delivery Gas Sampling Nasal Cannula, Hudson RCI Bi-Flo – K961150.

### F. Device Description

The SOFTECH Plus ETCO<sub>2</sub> Cannula is a non-sterile disposable, single patient use device that acts as an adjunct to oxygen therapy with its primary function providing a means to deliver low flow oxygen, while sampling part of the patients exhaled gas. The SOFTECH Plus ETCO<sub>2</sub> Cannula has a split nare blank with oxygen delivery through one nasal prongs while allowing sampling of the patient's exhaled gas from the corresponding nasal prongs.

### G. Indications for Use

The Hudson RCI SOFTECH® Plus ETCO<sub>2</sub> Nasal Cannula is an adjunct to oxygen therapy with its primary function being that of delivering low flow oxygen to a patient while providing a means to sample expired gas. It is intended for use in patients requiring oxygen therapy to improve blood oxygen levels while monitoring expired gas to determine ventilatory rate.

Patient Population: Infant, Pediatric, Adult

# H. Technological Characteristics and Material Comparison to the predicate

The proposed SOFTECH Plus ETCO<sub>2</sub> Cannula is substantially equivalent to the predicate device listed above in that the indications for use, the intended use, and fundamental scientific technology remain unchanged. **Table 1** summarizes the differences between the proposed and predicate devices.

Table 1 - Differences Between the Proposed and Predicate Devices

Features  Nasal Prongs	Predicate K961150 Double Lumen Oxygen Delivery Gas Sampling Nasal Cannula, Hudson RCI Bi-Rlo  Dual-channel nasal prong	Proposed SOFTECH® Plus ETCO <sub>2</sub> Cannula  Split nasal prong that directs oxygen	Performance Testing  ETCO <sub>2</sub>
(Nares)	that allows oxygen delivery and gas sampling from both nares	flow into one nare and samples expired gas from the other nare	Performance Testing with Simultaneous Oxygen Delivery
Oxygen supply tubing and CO <sub>2</sub> sampling line length	Oxygen supply tubing: 7 ft CO2 sampling line: 7 in	Oxygen supply tubing: 7 ft and 14 ft CO2 sampling line: 2 in, 7 ft and 14 ft	Performance Testing with Simultaneous Oxygen Delivery
Materials			
Nares Bolo Slide	Polyvinylchloride Polycarbonate or Polyvinylchloride	Polyvinylchloride Polyvinylchloride	Biocompatibility Testing: Cytotoxicity,
Tubing Clip	None	Polypropylene	Sensitization,
Lariat Tubing	Polyvinylchloride	Polyvinylchloride	Irritation,
Oxygen Supply Tubing	Polyvinylchloride	Polyvinylchloride	Genotoxicity, Implantation
CO <sub>2</sub> Sampling Line	Polyvinylchloride	Polyvinylchloride	
Oxygen Connector	Polyvinylchloride	Polyvinylchloride	
Tubing Connector	Polyvinylchloride	Polyvinylchloride	
Male and Female Luer Lock Connectors	Acrylic	Polycarbonate	
22mm Oxygen	None	Polypropylene	,

# Tab 006 - Section 011 - 510(k) Summary

Tubing Adaptor			
Adhesive	Cyclohexanone	Cyclohexanone	
PVC	PVC with DEHP	Non-DEHP PVC	DEHP Testing

### I. Performance Data

The proposed device was tested for ETCO<sub>2</sub> sampling at various oxygen flow rates, biocompatibility, and DEHP testing. The test results demonstrate that the device is substantially equivalent to the predicate device.

The tests performed are summarized in Table 2 below.

Table 2 – Performance Testing Summary

General Description
ETCO <sub>2</sub> performance in simulated conditions at various oxygen flow rates
Biocompatibility testing as per ISO 10993-1: cytotoxicity, sensitization, irritation,
genotoxicity and implantation testing
DEHP Testing

### J. Conclusion

The device data and test results demonstrate that the device is substantially equivalent to the predicate device.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WQ66-G609 Silver Spring, MD 20993-0002

June 4, 2014

Teleflex Medical, Inc.
Angela Bouse
Senior Regulatory Affairs Specialist
2917 Weck Drive
Research Triangle Park, NC 27709

Re: K132946

Trade/Device Name: SOFTECH® Plus ETCO2 Cannula

Regulation Number: 21 CFR 868.1400

Regulation Name: Carbon Dioxide Gas Analyzer

Regulatory Class: II

Product Code: CCK, CAT Dated: May 02, 2014 Received: May 05, 2014

### Dear Ms. Bouse:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</a> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,



Erin I. Keith, M.S.

Director

Division of Anesthesiology, General Hospital,
Respiratory, Infection Control and
Dental Devices

Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

K132946	
Device Name Hudson RCI SOFTECH® Plus ETCO2 Nasal Cannula	
Indications for Use (Describe)	
The Hudson RCI SOFTECH® Plus ETCO2 Nasal Cannula is a being that of delivering low flow oxygen to a patient while pro use in patients requiring oxygen therapy to improve blood oxygentilatory rate.	viding a means to sample expired gas. It is intended for
Patient Population: Infant, Pediatric, Adult	
·	
Type of Use (Select one or both, as applicable)	
☑ Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - C	ONTINUE ON A SEPARATE PAGE IF NEEDED.
Concurrence of Center for Devices and Radiological Health (CDRH)	
Todd D. Courtney -S	- 7.3v
2014.06.03 16:33:20 -04 00	TOTAL
· ·	

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."